Notably, there is increasing evidence that m6A regulators such as ALKBH5, YTHDF2, METTL3/14 and FTO can orchestrate PD-L1 expression, indicating that m6A inhibitors may regulate immune responses to anti-PD-1 therapy in HCC. Here, YTHDF2 is linked to hepatocellular carcinoma.